Showing all 2 results
Pazopanib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered, High-Density Film-Coated Tablet, packed exclusively in highly secure, child-resistant heavy-gauge HDPE bottles or specialized Alu-Alu blister strips to ensure the absolute chemical stability of the cytotoxic molecule and prevent accidental exposure.
Active Ingredient Strength Primary Clinical Function Pazopanib HCl INN/Ph.Eur. 200 mg (Base Equivalent) Dose-Modification Standard: Essential unit for precise dose reduction in patients experiencing severe hepatic toxicity or adverse drug reactions. Pazopanib HCl INN/Ph.Eur. 400 mg (Base Equivalent) Global Clinical Standard: Primary therapeutic unit designed to achieve the massive 800 mg daily protocol with minimal pill burden. Excipients Microcrystalline Cellulose / Sodium Starch Glycolate / Povidone K30 / Magnesium Stearate / Hypromellose / Titanium Dioxide Diluent / Superdisintegrant / Binder / Lubricant / Premium Cytotoxic-Barrier Film-Coating (Engineered specifically to seal the lethal HPAPI inside the tablet, completely protecting healthcare workers and caregivers from highly toxic dust exposure) *Pack Sizes: Bottles of 30 or 60 Tablets (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Stanozolol Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Uncoated or Film-Coated Tablet, packed in highly secure, moisture-resistant and child-resistant Alu-PVC or Alu-Alu blister strips to ensure the stability of the active hormonal ingredient.
Active Ingredient Strength Primary Clinical Function Stanozolol USP/Ph.Eur. 2 mg Clinical Standard: Targeted oral anabolic therapy for the prophylaxis of Hereditary Angioedema (HAE). Excipients Lactose Monohydrate / Microcrystalline Cellulose / Magnesium Stearate / Starch Diluent / Binder / Lubricant (Engineered for immediate gastric dispersion and reliable systemic absorption)
